Abstract Hypertrophic cardiomyopathy (HCM) is a myocardial disease associated with mutations in sarcomeric genes. Three mutations were found in ANKRD1, encoding ankyrin repeat domain 1 (ANKRD1), a transcriptional co-factor located in the sarcomere. In the present study, we investigated whether expression of HCM-associated ANKRD1 mutations affects contraction parameters after gene transfer in engineered heart tissues (EHTs). EHTs were generated from neonatal rat heart cells and were transduced with adeno-associated virus encoding GFP or myc-tagged wild-type (WT) or mutant (P52A, T123M, or I280V) ANKRD1. Contraction parameters were analyzed from day 8 to day 16 of culture, and evaluated in the absence or presence of the proteasome inhibitor epoxomicin for 24 h. Under standard conditions, only WT-and T123M-ANKRD1 were correctly incorporated in the sarcomere. T123M-ANKRD1-transduced EHTs exhibited higher force and velocities of contraction and relaxation than WT-P52A-and I280V-ANKRD1 were highly unstable, not incorporated into the sarcomere, and did not induce contractile alterations. After epoxomicin treatment, P52A and I280V were both stabilized and incorporated into the sarcomere. I280V-transduced EHTs showed prolonged relaxation. These data suggest different impacts of AN-KRD1 mutations on cardiomyocyte function: gain-offunction for T123M mutation under all conditions and dominant-negative effect for the I280V mutation which may come into play only when the proteasome is impaired.
hypertrophy and diastolic dysfunction, which develops in the absence of inciting factors such as hemodynamic overload or valvular disorder [23, 34] . HCM has an estimated prevalence of 1:500 in the general population and shows a complex pathophysiology with remarkable variability in disease development, age of onset and severity of symptoms [23, 34] . Whereas some patients exhibit an asymptomatic clinical history, others suffer from heart failure, malignant arrhythmia and/or sudden cardiac death (SCD). More than half of HCM patients have an apparent family history consistent with an autosomal dominant genetic trait [23] . Genetic analyses of HCM indicate a wide spectrum of genetic abnormalities [13, 19, 38] . The majority of mutations are located in genes encoding cardiac sarcomeric proteins, which play key roles in the generation, transmission or regulation of contractile force. Subsequent functional analyses of mutations in the sarcomeric components revealed that many HCM-associated mutations resulted in increased myofilament Ca 2? sensitivity [12, 26, 35, 42] , leading to higher force development and compromised relaxation at the same intracellular Ca 2? concentration. This is consistent with the echocardiographic features of HCM that are hypercontractility and diastolic dysfunction. The pathomechanisms by which mutations in genes encoding for Z/I-band components lead to HCM remain to be elucidated.
Ankyrin repeat domain 1 (ANKRD1), or alternatively termed cardiac ankyrin repeat protein (CARP), encoded by ANKRD1 is one of the earliest markers of the cardiac muscle cell lineage, downstream in the Nkx2.5 pathway that plays a pivotal role in cardiomyogenesis [50] . High levels of ANKRD1 are detectable in embryonic and fetal heart development stages, and a progressive decrease is observed in neonatal and adult hearts [18] . ANKRD1 level is elevated in hypertrophic and failing hearts, together with other fetal genes [8, 17, 20, 49] , suggesting a role of ANRRD1 in the regulation of ''fetal gene program'' during cardiac remodeling. ANKRD1 is also known as a corepressor of transcription and to be involved in the signaling pathway of NF-jB [21] . After a physiological level of stretch in fetal rat cardiomyocytes, ANKRD1 was shown to accumulate not only in the nuclei but also in the Z/Iband region of the sarcomere [25] , indicating shuttling of ANKRD1 in response to muscle stretch. Since ANKRD1 binds to the N2A domain of titin, which acts as a molecular spring to develop passive tension within extensible I-band region, it might be involved in a titin-N2A-based stretch sensor machinery (for review, see [22] ). ANKRD1 is also anchored at the Z/I-band region by another cytoskeletal protein, myopalladin, which plays a role in Z-disc assembly, myofibrillogenesis, and signaling in the Z/I-band [5] . Moreover, ANKRD1 interacts with muscle specific RING finger proteins MuRF1 and MuRF2 [46] . MuRF1/2 is sarcomere-associated E3 ubiquitin-ligases that conjugate ubiquitin to proteins destined to proteasome-mediated degradation [47] . This suggests that the known ANKRD1 degradation by the ubiquitin-proteasome system (UPS) [4, 36] could be mediated by MuRFs.
ANKRD1 mutations have been recently shown to be associated with both hypertrophic cardiomyopathy (HCM) [3] and dilated cardiomyopathy (DCM) [27] . We mainly focused our attention to the ones involved in HCM onset to a Genomic localization of ANKRD1 mutations associated with human hypertrophic cardiomyopathy (HCM) or dilated cardiomyopathy (DCM). Initiation and termination codons (ATG and TGA, respectively) are indicated. b Schematic structure of the plasmid encoding myc-tagged ANKDR1 or GFP. The cDNAs were cloned under the control of the MLC260 promoter and CMV-enhancer. The insert comprised between the two inverted terminal repeat (ITR) also contains the b-globin chimeric intron and the SV40 polyA signal. The plasmid dsAAV-CMVenh-MLC260-EGFP or -myc-ANKRD1 (about 6,100 bp) was packaged into adeno-associated virus serotype 6 investigate the specific pathomechanisms related to that disease. By analyzing HCM patients for mutations in AN-KRD1, we detected three HCM-associated missense mutations (P52A, T123M, and I280V), all of which showing increased binding of ANKRD1 to titin and myopalladin [3] . Interestingly, we also reciprocally identified HCM-associated mutations in the ANKRD1-binding N2A domain of titin and in the N-terminal domain of myopalladin, which increased or reduced binding to ANKRD1, respectively [3, 32] . These observations suggested that the assembly or binding of sarcomeric ANKRD1 to titin and/or myopalladin would be required for the maintenance of cardiac function, although the functional roles of ANKRD1 in the cytoplasm, especially at the Z/I-band are poorly understood. We hypothesized that ANKRD1 mutations might affect cardiac muscle contractility. In this study, we investigated the impact of gene transfer of HCM-associated ANKRD1 mutations on contraction parameters of engineered heart tissues (EHTs) derived from neonatal heart cells [15] .
Methods

Plasmid construction
Human wild-type (WT) and mutant (P52A, T123M, and I280V) ANKRD1 cDNAs were obtained by PCR from myctagged ANKRD1 constructs (Fig. 1) [3] . The eGFP sequence of dsAAV-CMVenh-MLC260-EGFP vector (kindly given by Dr. Oliver Müller, Heidelberg) [28] was excised and replaced by myc-tagged ANKRD1 cDNA fragments (Fig. 1) . The constructs were sequenced to ensure that no mutations were introduced.
AAV production and titer
Production of adeno-associated virus serotype 6 (AAV6) encoding either WT or mutant myc-ANKRD1 or GFP was performed as described previously (Fig. 1) [28] . AAV packaging plasmid pDP6rs was kindly provided by Prof. Jürgen Kleinschmidt (Heidelberg). AAV6 titers ranged from 5.8 9 10 11 to 9.7 9 10 11 vector genomes (vg) per ml.
Neonatal rat ventricular myocytes (NRVMs) culture, treatment and Western blot analysis Neonatal rats were sacrificed by decapitation, and ventricles were removed aseptically. Neonatal rat ventricular cardiomyocytes (NRVMs) were isolated as described previously [14, 48] . To enrich for cardiac myocytes, cells were preplated in a 10-cm dish at 37°C and 10 % CO 2 for 90 min. All unattached cells were transferred to a Falcon tube and spinned once at 600 rpm for 15 min at room temperature before being counted using a Neubauer chamber. A total of 3.3 9 10 5 NRVMs per well were plated on gelatin-coated (0.01 mg/ml in 19 PBS) 12-well plates and incubated at 37°C and 10 % CO 2 in the culture medium (MEM w/o glutamine, 10 % FCS, 10 % 5-bromo-2 0 -deoxyuridine (BrdU) and 1 % penicillin/streptomycin). AAV6-mediated transduction of NRVMs was performed by adding a MOI of 3,000-100,000 vg/cell directly before cell plating. Cell harvesting was performed 72 h after transduction. Twenty-four hours before harvesting NRVMs were treated with proteasome inhibitors, by adding the drug in fresh medium and then proceeding with a medium change. The reversible proteasome inhibitor MG132 (1 lM) or the irreversible proteasome inhibitor epoxomicin (500 nM) was used, both dissolved in 0.1 % of DMSO. Control cells were treated only with 0.1 % DMSO. For Western blot analysis, NRVMs were harvested 72 h after culture, proteins were extracted and Western blots were performed, as described previously [45] . Membranes were incubated with a polyclonal antibody directed against ANKRD1 (1:250) or the myc tag (Sigma-Aldrich; 1:1000). The secondary antibody used was POX anti-rabbit Ab (Dianova; 1:6000). Signal was detected by ECL Plus Western Blotting detection system substrate (Amersham).
Rat engineered heart tissue generation, transduction, and contraction measurements Generation of EHTs from neonatal rat heart cells was done as described previously [14, 15] . Briefly, a reconstitution mix (n = 12 for each ANKRD1 variant) containing 4.1 9 10 5 cells/EHT, bovine fibrinogen, including aprotinin, and Dulbecco's modified Eagle's medium (DMEM), including 1 % P/S, 1 % L-glutamine and 10 % FCS, and 29 DMEM [with 20 % horse serum (HS), 4 % chick embryo extract (CEE), 2 % P/S] matching the volume of fibrinogen and thrombin were prepared on ice. After preparation of the casting molds in 24-well plates by agarose solidification, silicone post racks were placed onto the dishes with pairs of posts reaching into each casting mold. For each EHT, a 100 ll reconstitution mix was mixed quickly with 3 ll thrombin and added into the agarose slot. After 2 h of incubation at 37°C in 7 % CO 2 , the racks were transferred to new 24-well plates with 1.5-ml fresh EHT medium (DMEM with 10 % HS, 2 % CEE, 1 % P/S, 33 lg/ml aprotinin, 10 lg/ml insulin).
EHTs were transduced with AAV6 encoding WT or mutant (P52A, T123M or I280V) ANKRD1 at an MOI of 1,000. The transduction was performed directly in the reconstitution mix before pipetting it into the agarose slots. To maintain the isotonic conditions, 29 DMEM was added matching the virus volume. Constructs were then cultured at 37°C in a 7 % CO 2 -humidified cell culture incubator for 15 days. At day 15, the EHTs were treated for 24 h with 500 nM epoxomicin (in 0.1 % DMSO). Contraction measurements were performed on days 8, 10, 13, 15 and 16, as described previously [14] [15] [16] . Briefly, contractions of EHTs were monitored by video-optical recording. Analysis of the recording was performed using a customized software (http://www.ctmv.de), based on figure recognition of the contracting muscle strip in a fully automated manner. Values for average force of contraction, contraction velocity and relaxation velocity were calculated with a specific custom-made algorithm [44] .
Immunofluorescence analysis
The entire EHTs were analyzed using confocal imaging. EHTs were rinsed with PBS and fixed in Histofix Ò (Carl Roth) overnight at 4°C. The samples were then removed from the silicon posts and treated for 24 h with a blocking solution (Tris-buffered saline 0.05 M, pH 7.4, 10 % FCS, 1 % BSA, 0.5 % Triton X-100) at 4°C. As primary antibodies we used monoclonal anti-myc (Life Technologies, 1:2000) and polyclonal antibody directed against cardiac myosin-binding protein C (cMyBP-C; 1:10000). Secondary antibodies were Alexa 488 anti-mouse (Molecular Probes, 1:800) and Alexa 546 anti-rabbit (Molecular Probes, 1:800). Finally, EHTs were mounted between a cover slip and a glass slide (26 9 76 mm; Thermo Scientific), and the fluorescence signal was analyzed using a Carl Zeiss confocal microscope (Zeiss LSM 510 META) with a 639-oil objective. Confocal images were recorded with a Zeiss LSM 5 Image system.
RT-qPCR analysis
Total RNA was extracted from EHTs using the SV Total RNA Isolation Kit (Promega) according to the manufacturer's instructions. RNA concentration, purity and quality were determined using the NanoDrop Ò ND-1000 spectrophotometer (Peqlab). RT was performed using oligo-dT primers with the RevertAid TM First Strand cDNA Synthesis Kit (ThermoScientific) from 100 ng RNA, and qPCRs were performed using SYBR green (Maxima SYBR Green/ROX qPCR Master Mix, ThermoScientific) and specific primers for atrial natriuretic peptide (Nppa), brain natriuretic . Cells were treated with 1 lM of MG132 (?MG132) or 500 nM of epoxomicin (?Epox) for 24 h before harvesting. Western blot membranes were stained with a polyclonal anti-ANKRD1 antibody. Control (-ctrl) corresponds to untransduced NRVMs peptide (Nppb), b-myosin heavy chain (Myh7) or a-skeletal actin (Acta1). G aS was used as an endogenous control to normalize the quantification of the target mRNAs for difference in the amount of total RNA added to each reaction. Experiments were performed on the ABI PRISM Ò 7900HT Sequence Detection System (Applied Biosystems). The amount of mRNA was estimated according to the comparative Ct method with the 2-DDC t formula.
Statistical analysis
Data were expressed as mean ± SEM. Statistical differences were analyzed using the one-way or two-way analysis of variance (ANOVA) followed by the Bonferroni adjustment for post hoc multiple comparison, or by the unpaired Student's t test, as indicated in the legend of each figure. A P value of less than 0.05 was considered to be statistically significant.
Results
Expression of wild-type and mutant-ANKRD1 in NRVMs
NRVMs (3.3 9 10 5 ) were plated and first transduced with different MOIs of AAV6 encoding GFP. Transduction efficacy was evaluated by GFP fluorescence (Fig. 2a) and Western blot analysis (Fig. 2b) . GFP protein level increased with increasing MOI from 3,000 to 30,000 vg/cell, and then saturated. We, therefore, used a MOI of 20,000 for transduction of NRVMs with AAV6 encoding WT-ANKRD1, mutant-ANKRD1 for 48 h. In contrast to GFP, the protein levels of exogenous WT-and mutantANKRD1s did not differ from endogenous ANKRD1 in untransduced NRVM at the baseline conditions, suggesting instability of the proteins. To evaluate whether exogenous ANKRD1 proteins are degraded by the UPS, cells were treated the last 24 h with MG132 or epoxomicin. Western blot analyses revealed marked stabilization of endogenous ANKRD1 as well as exogenous WT-and mutant-ANKRD1s by proteasome inhibitors, especially by epoxomicin (Fig. 2c) . Endogenous ANKRD1 but not exogenous ANKRD1s exhibited an upper band of ANKRD1, which could correspond to ubiquitinated-ANKRD1.
Contraction properties of EHTs expressing GFP
To investigate the effect of exogenous ANKRD1 on the contraction of EHTs, we first transduced AAV6 encoding GFP protein into EHTs. Force and velocities of contraction and relaxation were measured after 8, 10, 13 and 15 days of culture. Figure 3a shows that a MOI of 1,000 was sufficient to fully transduce EHTs with AAV6, a 20-fold lower D C B dose than that used in NRVMs (Fig. 2a) . This shows better transduction of AAV6 in the 3D format and is likely due to fibrin, which traps both cells and virus and brings them close to each other. Untransduced EHTs (CTRL) exhibited a time-dependent increase in force and in velocities of contraction and relaxation (Fig. 3) . None of the contraction parameters differed significantly between GFP-transduced and untransduced EHTs (Fig. 3) , indicating that AAV6 transduction at a MOI of 1,000 did not exert nonspecific toxicity in this model. We then analyzed the contraction of EHTs transduced with AAV6 encoding WT-ANKRD1 or each mutant-ANKRD1. EHTs transduced with WT-ANKRD1 showed a time-dependent increase in force and in velocities of contraction and relaxation until day 13 of culture (Fig. 4) . The contractile parameters of EHTs transduced with either P52A-ANKRD1 or I280V-ANKRD1 did not significantly differ from EHTs transduced with WT-ANKRD1. In contrast, force and velocities of contraction and relaxation were markedly higher at all time points in EHTs transduced with T123M-ANKRD1 than with WT-ANKRD1 (Fig. 4) .
Effect of proteasome inhibition on the contraction properties of EHTs
Because WT-and mutant-ANKRD1 proteins were stabilized by proteasome inhibitors (Fig. 2) , we treated half of the EHTs with 500 nM epoxomicin at day 15 for 24 h. Contraction parameters were then measured at day 16 in the absence (-) or presence (?) of epoxomicin treatment (Fig. 5) .
In the absence of epoxomicin, similar findings were obtained at day 16 compared to day 15. Parameters of contraction (force, velocities and times) did not differ among the groups, except that for T123M-ANKRD1-transduced EHTs, which exhibited higher force and velocities of contraction and relaxation than WT-transduced EHTs. Times of contraction and relaxation did not differ among the groups.
Treatment with epoxomicin for 24 h did not affect the force, velocities of contraction and relaxation, and contraction time in untransduced EHTs or in GFP-transduced EHTs. In contrast, relaxation time was prolonged in GFPtransduced and in I280V-ANKRD1-transduced EHTs after epoxomicin. Strikingly, force and velocities of contraction and relaxation were markedly reduced in EHTs transduced with WT-, P52A-or I280V-ANKRD1. In contrast to the other mutants, force and velocities of contraction and relaxation were not affected in T123M-ANKRD1-transduced EHTs after epoxomicin treatment. Consequently, force and velocities of contraction were still markedly higher in EHTs transduced with T123M-ANKRD1 than with WT-ANKRD1. Contraction time of T123M-ANKRD1-transduced EHTs was reduced after proteasome inhibition.
Immunofluorescence analysis of ANKRD1-transduced EHTs
In order to examine the localization of myc-tagged WT-ANKRD1 and mutant-ANKRD1s in EHTs, confocal microscopy was employed on transduced EHTs. In the absence of epoxomicin treatment, the number of mycpositive cardiomyocytes was low in all groups (data not shown). WT-ANKRD1 assembled in a striated pattern and showed alternation with cMyBP-C, suggesting that exogenous ANKRD1 is incorporated into the I/Z-band region (Fig. 6 ). Similar localization was observed for T123M-ANKRD1 (Fig. 6) . In contrast, P52A-and I280V-ANKRD1s were not clearly incorporated into the sarcomere (Fig. 6) .
Upon epoxomicin treatment, WT-and mutant-ANKRD1s were all found in the sarcomere and additionally in the nucleus (Fig. 6) . No myc-specific signal was detected in untransduced EHTs (CTRL), whereas GFP was diffusely distributed in all cardiac myocytes irrespective of the treatment (Fig. 6) . 
Evaluation of gene expression in ANKRD1-transduced EHTs
We then evaluated whether the expression of ANKDR1 mutations activated the fetal gene program of hypertrophy in EHTs after transduction and treatment with epoxomicin. Overall, transcript levels did not vary much between groups, and no significant differences in the mRNA levels of Nppa, Nppb, Myh7 and Acta1 were detected between WT-and mutant-ANKRD1 groups (Fig. 7) . On the other hand, Nppa mRNA level was lower in EHTs expressing WT-or mutant-ANKRD1 than in those expressing GFP, suggesting that ANKRD1 could negatively regulate the Nppa promoter as suggested previously [18] . ANKRD1 has also been shown to modulate the transcription of other sarcomeric genes, such as the regulatory myosin light chain 2v (Myl2), a-cardiac actin (Actc1), titin (Ttn), and cardiac troponin C (Tnnc1) [10, 50] . Therefore, we sought to evaluate whether stabilization of ANKRD1 by proteasome inhibition could modulate expression of these endogenous rat genes. None of them displayed significant difference among the groups, suggesting no specific regulation by WT-or mutant-ANKRD1 in EHTs (Fig. 7) . On the other hand, rat Ankrd1 mRNA level was much lower after proteasome inhibition than without (Fig. 8) .
Discussion
In the present study, we investigated whether the expression of WT-or HCM-associated ANKDR1 mutations would affect the contraction parameters after gene transfer in EHTs. We made use of the 24-well-fibrin EHT model that allows studying a relatively high number of uniformly transduced muscles in parallel [14] [15] [16] . The major findings of the present study are: (1) WT-and mutant-ANKRD1 proteins are instable in cardiac myocytes; (2) inhibition of the proteasome induced marked accumulation of ANKRD1 in the sarcomere and in the nucleus, which, in the case of WT and the P52A-and I280V-ANKRD1 mutant, was accompanied by depression of force; (3) transduction of EHTs with T123M-ANKRD1 increased force compared to WT-AN-KRD; and (4) most of the genes that have been suggested as target genes of ANKRD1 [10, 18, 50] were not regulated in EHTs transduced with either WT-or mutant-ANKRD1. Our finding that WT-and mutant-ANKRD1 protein levels were stabilized by proteasome inhibition in different cell systems supports the results of former studies showing that ANKRD1 turnover is regulated by the UPS [4, 36] . In addition, we provide evidence that proteasome inhibition favors the incorporation of ANKRD1 in the sarcomere and induces nuclear accumulation of ANKRD1 proteins.
Interestingly, previous data also showed accumulation of ANKRD1 in the myofibrils and in the nucleus after stretch [25] . Whether stretch and proteasome inhibition regulate similar pathways needs further investigation. In the absence of proteasome inhibition, only WT-and the T123M-ANKRD1 mutant were correctly incorporated in the sarcomere. It is worth noting that a T116M mutation, reported to be associated with anomalous pulmonary venous return, was found to increase the stability of AN-KRD1 protein [11] . Both T123M and T116M mutations are located in the same PEST region. The T116M mutation has been shown to confer higher protein stability due to alterations of the PEST region, which is known to be involved in rapid intracellular turnover [33] . The other two AN-KRD1 mutants showed a patchy pattern in cardiac myocytes of EHTs. These mutants do not alter the PEST region and are therefore highly unstable, degraded by the UPS.
Interestingly, the T123M-ANKRD1-transduced EHTs showed a marked increase in force development as well as faster kinetics of contraction and relaxation than WT-ANKRD1-transduced EHTs. The difference remained after proteasome inhibition. These observations suggest that the ''sarcomeric'' T123M rather than the ''nuclear'' T123M is responsible for the higher force generation and faster kinetics, because no nuclear T123M-ANKRD1 was detected in the absence of proteasome inhibition. This gain-of-function behavior of an HCM-associated mutation is consistent with previous studies that have demonstrated an increase in myofilament Ca 2? sensitivity caused by HCM-associated sarcomere mutations [12, 19, 26, 35, 42, 43] . Furthermore, several murine HCM models carrying a sarcomeric gene mutation showed enhanced contractile function of cardiac muscles due to the increase in Ca 2? sensitivity [1, 7, 9, 30] (and Stöhr et al., personal unpublished data), and previous data showed that gene transfer of mutant FHL1 associated with HCM resulted in altered force and kinetics of contraction and/or relaxation of EHTs [14] . Our data support the concept of hypercontractility and/or faster kinetics as a common mechanism of HCMrelated mutations, and extend it to proteins of the Z/I-band region of the sarcomere.
In contrast to the T123M mutant, gene transfer of P52A-and I280V-ANKRD1 did not augment force and velocities of contractions in EHTs, presumably because the mutants were degraded by the UPS and therefore not incorporated into the sarcomere. Inhibition of the proteasome system led to their stabilization, their incorporation into the I/Z-band region of the sarcomere as well as in the nucleus. In these conditions, whereas most of the parameters did not differ between EHTs transduced with P52A-or I280V-ANKRD1 than from WT-ANKRD1-transduced EHTs, relaxation time was higher in I280V-ANKRD1 than in WT-ANKRD1 group. This suggests that I280V mutation prolonged relaxation when the UPS is impaired, which could lead to diastolic dysfunction. Therefore, pathological mechanisms differ among the ANKRD1 mutations, as previously shown Fig. 7 Evaluation of gene expression by RT-qPCR after EHT transduction with myc-tagged WT-and mutant-ANKRD1 and proteasome inhibition. Total RNA was extracted from EHT transduced with AAV6 encoding WT-ANKRD1, mutant-ANKRD1s, GFP or from untransduced EHTs (CTRL) at day 16 after 24 h treatment with 500 nM epoxomicin. cDNA was obtained from RNA using oligo-dT primers. PCR was performed using SYBR green and specific primers for a atrial natriuretic peptide (Nppa), b brain natriuretic peptide (Nppb), c a-skeletal actin (Acta1), d b-myosin heavy chain (Myh7), e regulatory myosin light chain 2v (Myl2), f titin (Ttn), g a-cardiac actin (Actc1), and h cardiac troponin C (Tnnc1). Data were normalized to Gas and related to CTRL (n = 2-4 samples) ) or without (-Epoxo) 500 nM epoxomicin. cDNA was obtained from RNA using oligo-dT primers. PCR was performed using SYBR green and specific primers for rat Ankrd1 mRNA. Data were normalized to Gas. Data are expressed as mean ± SEM. ***P \ 0.001 vs. untreated EHTs, Student t test. Number of samples is indicated in the bars for FHL1 mutations after gene transfer in EHTs [13] . Furthermore, this supports the general view that, even if a higher Ca 2? sensitivity is a fairly frequent feature of HCM, some HCM-associated mutations do not exhibit increased myofilament Ca 2? sensitivity and may exert their pathological roles via other mechanisms [29, 40] .
Further investigations are required to better understand the role of ANKRD1 in the regulation of cardiac muscle contractility. ANKRD1 is physiologically expressed in embryonic and fetal hearts and progressively decreases after birth [18] . ANKRD1 is detected at low levels in healthy adult heart, but its level increases again in pathological conditions such as hypertrophied and failing heart [2, 8, 17, 20, 49] . It is possible that the higher amount of ANKRD1 protein in pathological conditions is, at least in part, related to UPS impairment. Particularly, proteasome activities are reduced in human HCM, DCM and heart failure, as well as after adrenergic stress or with aging in a mouse model of HCM [31, 37, 39, 41] . Therefore, one could imagine that UPS impairment in cardiac diseases such as HCM may reveal the pathological role of mutant-ANKRD1. Accumulation of ANKRD1 with UPS impairment may trigger a series of transcriptional changes leading to HCM development. This effect would need more time to onset the disease and could be related more directly to a general remodeling of the tissue. In the present study, we showed that proteasome inhibition did not affect the contraction parameters of untransduced EHTs, suggesting that epoxomicin itself (and stabilization of endogenous rat ANKRD1) is not toxic. On the other hand, the association of epoxomicin and the expected stabilization of proteins after AAV6-mediated transduction showed different alterations: increased relaxation time with GFP, marked decrease in force, and in contraction and relaxation velocities with WT-, P52A-and I280V-ANKRD1 exhibited, and finally, reduced contraction time with T123M mutant. These alterations are likely to be a direct effect of ''sarcomeric'' WT-and mutant-ANKRD1 in the I/Z-band region of the sarcomere, although we cannot exclude an effect in the nucleus.
Localization of ANKRD1 in the nucleus after proteasome inhibition is consistent with a primary role as a transcription co-repressor [18, 50] . Indeed, it has been shown that ANKRD1 inhibits Nppa and Tnnc1 promoters [18] , as well as the expression of Myl2 [50] , Ttn and Actc1 [10] . This role is also supported by the increased expression of muscle LIM protein (Crsp3) in mice lacking the 3 genes of the MARF family, including Ankrd1 [6] . In the present study, we evaluated the expression of most of the genes that have been shown to be regulated by ANKRD1. We confirmed that Nppa could be down-regulated by ANKRD1, although no major differences were observed between the different ANKRD1 genotypes. On the other hand, Nppb, Acta1, Myh7, Mlc2v, Actc1, Ttn and Tnnc1 mRNA levels did not significantly differ among the groups, suggesting that these genes are not regulated by ANKRD1 under our experimental conditions. These results are not consistent with data obtained by other groups [10, 18, 50] , adding complexity to the enigmatic role of ANKRD1 in cardiac myocytes [24] . On the other hand, the reduction of rat Ankrd1 mRNA after proteasome inhibition suggests that ANKRD1 inhibits its own promoter in an autoinhibitory feedback loop as recently suggested [11] .
In conclusion, we provide evidence that ANKRD1 mutants act differently on the contractile properties of cardiac myocytes. The T123M mutation is a gain-of-contractile function mutation, supporting the paradigm derived from most sarcomeric mutations associated with HCM and extending it to the I-Z-band proteins. The I280V mutation is a dominant-negative mutation which may come into play only when the UPS is impaired.
